Telo Genomics Corp. is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as part of the TELO-DMRD clinical validation study (NCT05530096). The study, conducted in collaboration with McGill University in Montreal, Canada, aims to validate the sensitivity of Telo's MRD assay and establish the clinical utility of TELO-DMRD for MRD enumeration.
The TELO-DMRD study utilizes Adaptive Biotechnologies’ clonoSEQ assay technology to assess MRD in up to ten patients, with potential for expansion based on initial results. The first patient samples have already been analyzed. Telo's MRD clinical trials with McGill University have two primary objectives: to identify and quantify MRD cells circulating in the patient's blood post-marrow transplantation and to profile these isolated circulating MRD cells using Telo's proprietary TeloView technology to assess disease aggressiveness.
MRD Assessment in Oncology
Minimal residual disease (MRD) testing is becoming increasingly important in assessing treatment response and guiding therapeutic decisions in oncology. The MRD global testing market is projected to reach USD 4.1 billion by 2032, driven by advancements in drug development technologies and a growing emphasis on personalized healthcare. clonoSEQ is widely accepted as the MRD industry leader in multiple myeloma with a routinely achieved sensitivity of beyond 10-6 and has gained the trust of the diagnostic community.
TeloView Technology
Telo Genomics' TeloView technology is designed to assess disease aggressiveness in individual MRD cells. By combining quantitative analysis of 3D telomeres with molecular biology and artificial intelligence, Telo is developing products aimed at improving patient care by serving the needs of pathologists, clinicians, academic researchers, and drug developers. The benefits of Telo's technology have been demonstrated in over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients with various cancers and Alzheimer's disease.
Liquid Biopsy Approach
The MRD tests being developed by Telo Genomics are designed to be liquid biopsy-based, a less invasive and more easily replicated approach compared to traditional diagnostic methods. This aligns with the growing interest in liquid biopsies within the medical community. Telo's lead application, TELO-MM, is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma.
